UNSPSC 51343103: Clevudine

This classification denotes a reverse transcriptase inhibitor with the molecular formula C10H13FN2O5, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier IN51MVP5F1, chemically known as 2,4(1h,3h)-pyrimidinedione, 1-(2-deoxy-2-fluoro-beta-l-arabinofuranosyl)-5-methyl- but generally known as clevudine, which bears US NIH Compound Identifier 73115. European Medicines Agency schedules Clevudine in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB06656MIG.

UNSPSC 51343103 Clevudine is a Commodity code that nominally designates an antiviral pharmaceutical active ingredient; however, recent state and local opportunities tagged under this code show little direct relevance to clevudine procurement. The Illinois Department of Public Health awarded a $2,999,999.11 pharmaceutical warehouse piggyback contract through the MMCAP Infuse consortium to Chartwell Rx LLC for Doxycycline Hyclate 100mg and Ciprofloxacin Hydrochloride 500mg tablets, and Seminole County, Florida solicited 1,900 units of Naloxone and 800 Safe Drug Deactivation Systems annually. Neither opportunity involves clevudine. State and local procurement under this code appears limited in recent activity, with tagging appearing to diverge from the actual products being sourced — antibiotics and opioid-overdose interventions rather than the antiviral agent the code nominates.

The available recent opportunities originate from a state health department and a county government, both in the southeastern and Midwest regions. The Illinois Department of Public Health contract, awarded in August 2026, represents a completed piggyback purchase through a cooperative vehicle rather than a direct competitive solicitation, while Seminole County's IFB for naloxone and drug deactivation systems (posted June 30, 2026, with response due July 26, 2026) targets community health infrastructure. No other jurisdictions or additional representative opportunities under this code appear in the recent record. Firms pursuing activity under UNSPSC 51343103 should verify actual product lines and vendor qualifications against the specific pharmaceuticals state and local health departments are buying, as code assignment does not reliably predict scope.